Treatment of Inherited Factor VII Deficiency

Study Overview
=================
Brief Summary
-----------------
FVII deficiency is a rare coagulation disorder. A limited number of patients are found in most treatment centres and countries. Treatment demands vary considerably amongst FVII deficient patients. Therefore, regular clinical studies will meet with recruitment problems in this particular patient population. The present study intends to elucidate the bleeding patterns in a well-defined collective of FVII deficiency patients who are carefully characterised, to document the actual use of different treatment modalities in different subgroups and to evaluate the efficacy and safety of current available treatment modalities in bleedings, surgery and prophylaxis. The purpose is to gain some evidence based knowledge of treatment of patients with FVII deficiency - an area where treatment decisions are made more on personal clinical experience than on consolidated clinical evidence. This study intends to register treatment practices as they are actually performed - in a structured and documented way.

Detailed Description
-----------------
To describe the treatment modalities and outcomes of: - bleeding episodes - surgery - prophylaxis in a well defined, international cohort of FVII deficient patients characterised following the methodology used by the International Factor VII deficiency Study Group (IF7SG). To evaluate the presence (in already treated patients) and/or the appearance of inhibiting antibodies to FVII and/or therapy-related thrombosis. Study Design: Prospective observational study on treatment of FVII deficiency patients. This is an outcome study conducted through the procedures set up by the IF7SG, in patients already enrolled or newly enrolled in the database. Study population and products: Patients with FVII deficiency (levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency) can be enrolled. All pharmaceutical products considered useful for treatment of FVII deficiency by the centres can be included in the study. Key assessments: The database is set up to capture the following assessments, if available: Bleeding episodes: • Recording of bleeding location, symptom onset and treatment onset & location • Recording of substitution therapy, concomitant medications and concomitant illness • Recording of 6 hour treatment evaluation for bleeding episodes • Recording of re-bleeding episodes Surgery/delivery: • Recording of surgery description , date of surgery and indication • Recording of substitution therapy, concomitant medications and concomitant illness during surgery • Recording of antifibrinolytic drugs used prior, during and/or after surgery •Recording of • Recording of overall treatment evaluation Prophylaxis: • Recording of prophylaxis type (primary/secondary), indication for prophylaxis and start/stop date •Recording of prophylaxis therapy, concomitant medications and concomitant illness • Recording of bleeding episodes during prophylaxis •Recording of clinical prophylaxis evaluation For all: Laboratory values (PT/INR, APTT, FVII:C, platelet count, fibrinogen, inhibitor samples) at time points specified in section 7.3. Adverse events (including thrombotic events, anaphylactic reactions, DIC reactions, Re- bleedings and mortality) Recording of 30 day treatment evaluation (excellent, effective, partly effective, ineffective or not evaluable) Duration of hospital stay (ward, ICU) within 30 days after first product treatment • Mortality within 30days after first product administration

Official Title
-----------------
Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study

Conditions
-----------------
Factor VII Deficiency

Intervention / Treatment
-----------------
* Drug: plasma derived Factor VII
* Drug: recombinant FVIIa
* Drug: Fresh Frozen Plasma
* Drug: Activated Prothrombin Complex Concentrates
* Drug: Virus Inactivated plasma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent by the patient or next of kin or legally acceptable representative to collect data on treatment of a given bleeding episode, surgical event or prophylactic regimen as specified in the protocol. If informed consent is provided by the next of kin or legally acceptable representative, consent must also be obtained from the patient as soon as he/she is able to do so.Informed consent should preferentially be obtained before initiation of treatment or as a minimum before entry of data into the database. 2.Males and females 0 to 90 years of age. 3. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by the treating physician can be enrolled. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Factor VII Deficient Patients<br>Patients affected by Inherited Factor VII deficiency undergoing treatment for bleeding episodes, surgery , prophylaxis.Any patient with levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by his/her treating physician can be enrolled. | Drug: plasma derived Factor VII<br>* Treatment of bleeding episodes,treatment during surgery and prophylaxis<br>* Other names: Factor VII, Baxter Immuno (plasma-derived);Drug: recombinant FVIIa<br>* Treatment of bleeding episodes,treatment during surgery and prophylaxis<br>* Other names: Novoseven;Drug: Fresh Frozen Plasma<br>* Treatment of bleeding episodes,treatment during surgery and prophylaxis<br>* Other names: Blood Transfusion Centre Fresh Frozen Plasma;Drug: Activated Prothrombin Complex Concentrates<br>* Treatment of bleeding episodes,treatment during surgery and prophylaxis<br>Drug: Virus Inactivated plasma<br>* Treatment of bleeding episodes,treatment during surgery and prophylaxis<br>* Other names: Octaplas;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Factor VII levels | To describe the treatment modalities and clinical and laboratory outcomes in: -bleeding episodes - surgery - prophylaxis in a well defined, international cohort of FVII deficient patients characterised following the methodology used by the IF7SG. | Time 0 (before treatment), 15 minutes and 1 month after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Inhibitor Development | To evaluate the presence (in already treated patients) and/or the appearance of inhibiting antibodies to FVII. | Monthly | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inherited Factor VII deficiency, Inhibitor development in Factor VII deficiency, Bleeding in Factor VII Deficiency, Surgery in Factor VII deficiency, Prophylaxis in Factor VII Deficiency